1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-14.09%
Cash & equivalents declining -14.09% while Drug Manufacturers - Specialty & Generic shows -4.26% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
18.78%
Short-term investments yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
3.64%
Below half the Drug Manufacturers - Specialty & Generic median of -2.89% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
-4.81%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of -0.21%. Jim Chanos might see a serious red flag in ballooning receivables.
15.72%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.87%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
33.22%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
7.27%
Below half the Drug Manufacturers - Specialty & Generic median of -1.01%. Jim Chanos would question if the company faces working capital strain.
14.83%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of -1.06%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
0.04%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-0.64%
Near the Drug Manufacturers - Specialty & Generic median of -0.81%. Charlie Munger would see standard intangible growth relative to sector norms.
-0.18%
Below half of Drug Manufacturers - Specialty & Generic median of -0.99%. Joel Greenblatt sees relatively minimal intangible expansions vs. peers.
-1.37%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
-27.78%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
3795.05%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
1.10%
Below half the Drug Manufacturers - Specialty & Generic median of -1.17%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
2.21%
Below half the Drug Manufacturers - Specialty & Generic median of -1.08%. Jim Chanos might see potential stagnation or distress vs. peers.
11.51%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
26.07%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
5.31%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
32.74%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
-4.65%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
24.09%
Below half Drug Manufacturers - Specialty & Generic median of -1.83%. Joel Greenblatt sees more conservative short-term leverage than peers.
-23.66%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
1.36%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
17.74%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.08%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-14.87%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.28%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
2.39%
Below half Drug Manufacturers - Specialty & Generic median of -1.31%. Joel Greenblatt sees a much lower liability expansion vs. peers.
9.09%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-2.96%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.06%. Joel Greenblatt sees stronger retained profit growth vs. peers.
6.54%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
1.92%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.05%. Joel Greenblatt sees stronger equity growth vs. peers.
2.21%
Below half Drug Manufacturers - Specialty & Generic median of -1.28%. Jim Chanos suspects a major slowdown or distress.
15.98%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-4.65%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.16%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
0.44%
Below half of Drug Manufacturers - Specialty & Generic median -0.09%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
